Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19-Reference-Cited by-同舟云学术

Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19

Published:2021-08 Issue:8 Volume:29 Page:2412-2423
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Capone Stefania^ORCID,Raggioli Angelo^ORCID,Gentile Michela,Battella Simone^ORCID,Lahm Armin,Sommella Andrea^ORCID,Contino Alessandra Maria,Urbanowicz Richard A.^ORCID,Scala Romina,Barra Federica,Leuzzi Adriano,Lilli Eleonora,Miselli Giuseppina,Noto Alessia,Ferraiuolo Maria,Talotta Francesco,Tsoleridis Theocharis^ORCID,Castilletti Concetta,Matusali Giulia,Colavita Francesca,Lapa Daniele,Meschi Silvia,Capobianchi Maria,Soriani Marco,Folgori Antonella^ORCID,Ball Jonathan K.^ORCID,Colloca Stefano,Vitelli Alessandra

Funder

Medical Research Council

European Commission

Horizon 2020 European Innovation Council Fast Track to Innovation

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference25 articles.

1. A Review of SARS-CoV-2 and the Ongoing Clinical Trials;Tu;Int. J. Mol. Sci.,2020

2. Chimpanzee adenoviral vectors as vaccines - challenges to move the technology into the fast lane;Vitelli;Expert Rev. Vaccines,2017

3. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults;Green;Sci. Transl. Med.,2015